Search by Abstract Number Results

Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Wilson Bautista-Molano¹, Ingrid Ramirez-bolivar², Cristina Pinilla-Forero³ and Luz A Ruiz⁴, ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²Janssen, Bogotá, Colombia, ³Janssen, Bogotá, ⁴CODENTMED, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…
Abstract Number: 1904 • ACR Convergence 2023
Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs
Douglas White¹, Maya Buch², Suzanne Murray³, Diane Caballero⁴, Orsolya Nagy⁵ and Tsutomu Takeuchi⁶, ¹Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ³AXDEV Group Inc, Brossard, QC, Canada, ⁴AbbVie, Inc., Chicago, IL, ⁵AbbVie, Inc., Budapest, Hungary, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan
Background/Purpose: Treat-to-target (T2T) is a widely established and accepted approach in RA management, but its real-world implementation is suboptimal1. Further primary research is required to…
Abstract Number: 1904 • ACR Convergence 2022
Is Treating Painful Hand Osteoarthritis with Hormone Replacement Therapy Feasible? Primary Results from a Randomised Controlled Trial in Post-menopausal Women
Jennifer Williams¹, Mae Chester-Jones¹, Megan Goff², Anne Francis¹, Gretchen Brewer¹, Ioana Marian¹, Malvika Gulati¹, Charles Mackworth-Young³, Victoria Glover⁴, Sarah Lamb¹, Tonia Vincent⁵, Katy Vincent¹, Susan Dutton¹ and Fiona Watt⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Oxford, London, United Kingdom, ³Imperial College Healthcare NHS Trust, London, United Kingdom, ⁴White Horse Medical Practice, Faringdon, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁶Imperial College London, London, United Kingdom
Background/Purpose: Hand osteoarthritis (OA) is more common in females and relative risk increases further around the age of menopause, potentially implicating sex hormone deficiency. There…
Abstract Number: 1904 • ACR Convergence 2021
“Why Does My Knee Hurt After I Got My Knee Replaced?”: Evaluation of Neuropathic-like Symptoms and Objective Signs of Neuropathy Post-Knee Replacement in Patients with Knee Osteoarthritis
Devin Driscoll¹, Priyanka Ballal¹, Na Wang², Laura Frey-Law³, Cora Lewis⁴, Michael Nevitt⁵ and Tuhina Neogi¹, ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA, ³University of Iowa, Iowa City, IA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵University of California San Francisco, Orinda, CA
Background/Purpose: Some people with knee osteoarthritis (OA) have persistent pain post-knee replacement, but why this occurs is not fully understood. One possibility is post-surgical neuropathy.…
Abstract Number: 1904 • ACR Convergence 2020
Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis
Xenofon Baraliakos¹, Rebecca Bolce², David Sandoval², Soyi Liu-Leage³, Vladimir Geneus³, David Adams³, Atul Deodhar⁴, Jessica Walsh⁵ and Joachim Sieper⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Eli Lilly and Company, Indianapolis, ³Eli Lilly and Company, Indianapolis, IN, ⁴Oregon Health & Science University, Portland, OR, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…
Abstract Number: 1904 • 2019 ACR/ARP Annual Meeting
IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients
Renaud Felten ¹, Nicolas Meyer ¹, P Duffaut ², D Saadoun ³, Eric Hachulla ⁴, Pierre Yves Hatron ⁴, Carine Salliot ⁵, Aleth Perdriger ⁶, Jacques Morel ⁷, Arsène Mekinian ⁸, Olivier Vittecoq ⁹, Jean Marie Berthelot ¹⁰, Emmanuelle Dernis ¹¹, Véronique Le Guern ¹², Philippe Dieudé ¹³, Claire Larroche ¹⁴, Christophe Richez ¹⁵, Thierry Martin ¹, Charles Zarnitsky ¹⁶, Gilles Blaison ¹⁷, P Kieffer ¹⁸, François Maurier ¹⁹, Stéphanie Rist ⁵, Patrice Cacoub ²⁰, Emmanuel Andres ²¹, Emmanuel Chatelus ¹, Christelle Sordet ¹, Jean Sibilia ¹, Cécile Arnold ¹, Mira Tawk ¹, Ouafaa Aberkane ¹, Raphaele Seror ²², Lise Holterbach ¹, Xavier Mariette ²² and Jacques-Eric Gottenberg²³, ¹Strasbourg University Hospital, Strasbourg, France, ²Bordeaux University Hospital, Bordeaux, Aquitaine, France, ³Pitie Salpetrière Hospital, APHP, Paris, France, ⁴Lille University Hospital, Lille, France, ⁵Orleans Hospital, Orleans, France, ⁶Rennes University Hospital, Rennes, France, ⁷Montpellier University Hospital, Montpellier, France, ⁸Saint-Antoine Hospital, APHP, Paris, France, ⁹Rouen University Hospital, ROUEN, France, ¹⁰Nantes University Hospital, Nantes, France, ¹¹Le Mans Hospital, Le Mans, France, ¹²Cochin Hospital, APHP, PARIS, France, ¹³Bichat Hospital, APHP, PARIS, ¹⁴Avicenne Hospital, PARIS, France, ¹⁵Bordeaux University Hospital, Bordeaux, France, ¹⁶Le Havre Hospital, Le Havre, ¹⁷Colmar Hospital, Colmar, France, ¹⁸Mulhouse Hospital, Mulhouse, France, ¹⁹Metz Hospital, Metz, France, ²⁰Pitie Salpéterière, APHP, Paris, France, ²¹CHU Strasbourg, strasbourg, ²²Bicetre Hospital, APHP, Paris, France, ²³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: IL-6 is suspected to play an important pathogenic role in primary Sjögren’s syndrome (pSS) through its crucial roles in B-cell activation, and T-cell polarization,…
Abstract Number: 1904 • 2018 ACR/ARHP Annual Meeting
Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases
Rosebeth Kagwiria¹, Ruifang Liang¹, Alexandru Matei¹, Niclas Sihler², Chih-Wei Chen¹, Thomas Burris³, Oliver Distler⁴, Georg Schett¹ and Jörg Distler¹, ¹Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany, ²Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of pharmacology and physiology, Saint Luis University-school of medicine, Florida, USA, St. Louis, Missouri, MO, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The Retinoic-acid related Orphan Receptor-alpha (RORα) is a member of the nuclear receptor superfamily and a ligand-dependent transcription factor implicated in a wide range…
Abstract Number: 1904 • 2017 ACR/ARHP Annual Meeting
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
Gerd R. Burmester¹, Joel Kremer², Filip van Den Bosch³, Yihan Li⁴, Yijie Zhou⁴, Ahmed A. Othman⁵, Aileen L. Pangan⁴ and Heidi S. Camp⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ²Albany Medical College, Albany, NY, ³Rheumatology, Ghent University Hospital, Gent, Belgium, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA) is an oral, selective JAK-1 inhibitor in development for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA) and…
Abstract Number: 1904 • 2016 ACR/ARHP Annual Meeting
Elevated GITRL Is Associated with Multi-Organ Involvement and Increased Disease Activity of Primarty Sjogren’s Syndrome and Promotes Pathogenic Th1/17 Differentiation
Xiaolin Sun¹, Yuzhou Gan Sr.², Jing He³ and Zhanguo Li⁴, ¹People's hospital,Peking University, Beijing, China, ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ³Peking Univerisity People's Hospital, Beijing, China, ⁴Peking University People's Hospital, Beijing, China
Background/Purpose: Accumulating data showed that Glucocorticoid-induced Tumor Necrosis Factor Receptor Family-related Protein (GITR), with its ligand (GITRL), plays an important role in promoting T-cell-mediated immunity…
Abstract Number: 1904 • 2015 ACR/ARHP Annual Meeting
Development of the Mawdsley Calcinosis Questionnaire (MCQ) Version 1 – a Patient-Reported Outcome Measure (PROM) for Systemic Sclerosis Related Calcinosis (SSc-Ca)
Lesley Ann Saketkoo¹, Kim Fligelstone², Evan Busman³, Angela Christensen⁴, Sophia Cenac⁵, Samara Khalique⁶, Andrew Aubin⁷, Veronika K. Jaeger⁸, Anne Mawdsley⁹, Jessica K. Gordon¹⁰, Randi Kaufman¹¹, Murray Baron¹², Virginia D. Steen¹³ and Tracy M. Frech¹⁴, ¹Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ³Atlanta Scleroderma Support Group, Atlanta, GA, ⁴Tulane University School of Medicine, New Orleans, LA, ⁵Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, New Orleans, LA, ⁷Louisiana State University School of Medicine, New Orleans, LA, ⁸Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁹Raynaud's & Scleroderma - Care and Support UK, Cheshire, United Kingdom, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Lousiana State University Health Sciences Center - School of Public Health, New Orleans, LA, ¹²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ¹³Rheumatology, Georgetown University Medical Center, Washington, DC, ¹⁴Div of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: SSc-Ca is a poorly understood vascular complication of SSc that usually related to extreme constant pain and infection/amputation risk for persons living with SSc-Ca…
Abstract Number: 1904 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Isotype Testing to Identify Individuals in the Preclinical Period of Rheumatoid Arthritis
M. Kristen Demoruelle¹, Anthony Kahr¹, Mark C. Parish¹, Marie L. Feser¹, Ryan W. Gan², Jason R. Kolfenbach¹, William R. Gilliland³, Jess D. Edison³, Michael H. Weisman⁴, James R. O'Dell⁵, Ted R. Mikuls⁶, Richard M. Keating⁷, Peter K. Gregersen⁸, Jane H. Buckner⁹, Jill M. Norris², V. Michael Holers¹⁰ and Kevin D. Deane¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Walter Reed National Military Medical Center, Bethesda, MD, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Scripps Clinic, La Jolla, CA, ⁸Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA)-related autoantibody (Ab) testing for Abs to cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) are used in the clinical diagnosis of…
Abstract Number: 1904 • 2013 ACR/ARHP Annual Meeting
Gene Expression In Whole Blood Predicts The Abatacept–Methotrexate Combination Responsiveness In Rheumatoid Arthritis: Preliminary Results From The Power Doppler Ultrasonography IM101-179 Study
T Lequerré¹, C Derambure¹, Maria-Antonietta d'Agostino², M Hiron³, P Gaudin⁴, C Gaillez⁵, M Le Bars⁶ and O Vittecoq¹, ¹Rouen University Hospital & Inserm U905, Rouen, France, ²AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ³Rouen University Hospital & Inserm, Rouen, France, ⁴CHU Hôpital Sud, Grenoble, France, ⁵Bristol-Myers Squibb, Rueil Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: The overall response rate (defined as low disease activity [LDA] related to DAS28[CRP]) to abatacept associated with MTX was 57.1% at 6 months in…
Abstract Number: 1904 • 2012 ACR/ARHP Annual Meeting
Patterns of Gout Treatment and Related Outcomes in US Community Rheumatology Practices: the Relation Between Gout Flares, Time in Treatment, Serum Uric Acid Level and Urate Lowering Therapy
Max I. Hamburger¹, John RP Tesser², John L. Skosey³, Allan H. Morton⁴ and Karl M. Kilgore⁵, ¹Rheumatology Associates, Melville, NY, ²AZ Arthritis Rheum Assoc, Paradise Valley, AZ, ³Illinois Bone & Joint Institut, Chicago, IL, ⁴Warren, MI, ⁵Cetus Group, LLC, Hunt Valley, MD
Background/Purpose: Study patterns of gout treatment and related outcomes in US community rheumatology practices, specifically the relation between likelihood and severity of gout flares, time…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].